• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

A comprehensive assessment of the cost of multiple sclerosis in the United States.

作者信息

Whetten-Goldstein K, Sloan F A, Goldstein L B, Kulas E D

机构信息

Center for Health Policy Research and Education, Duke University, Durham, North Carolina 27708, USA.

出版信息

Mult Scler. 1998 Oct;4(5):419-25. doi: 10.1177/135245859800400504.

DOI:10.1177/135245859800400504
PMID:9839302
Abstract

Comprehensive data on the costs of multiple sclerosis is sparse. We conducted a survey of 606 persons with MS who were members of the National Multiple Sclerosis Society to obtain data on their cost of personal health services, other services, equipment, and earnings. Compensation of such cost in the form of health insurance, income support, and other subsidies was measured. Survey data and data from several secondary sources was used to measure costs incurred by comparable persons without MS. Based on the 1994 data, the annual cost of MS was estimated at over $34,000 per person, translating into a conservative estimate of national annual cost of $6.8 billion, and a total lifetime cost per case of $2.2 million. Major components of cost were earnings loss and informal care. Virtually all persons with MS had health insurance, mostly Medicare/Medicaid. Health insurance covered 51 per cent of costs for services, excluding informal care. On average, compensation for earnings loss was 27 per cent. MS is very costly to the individual, health care system, and society. Much of the cost (57 per cent) is in the form of burdens other than personal health care, including earnings loss, equipment and alternations, and formal and informal care. These costs often are not calculated.

摘要

相似文献

1
A comprehensive assessment of the cost of multiple sclerosis in the United States.
Mult Scler. 1998 Oct;4(5):419-25. doi: 10.1177/135245859800400504.
2
The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.美国多发性硬化症的经济负担:直接和间接成本的估计。
Neurology. 2022 May 3;98(18):e1810-e1817. doi: 10.1212/WNL.0000000000200150. Epub 2022 Apr 13.
3
Costs and quality of life of multiple sclerosis in Switzerland.瑞士多发性硬化症的成本与生活质量
Eur J Health Econ. 2006 Sep;7 Suppl 2:S86-95. doi: 10.1007/s10198-006-0383-9.
4
Perceptions of informal care givers: health and support services provided to people with multiple sclerosis.非正规照护者的认知:为多发性硬化症患者提供的健康和支持服务。
Disabil Rehabil. 2010;32(6):500-10. doi: 10.3109/09638280903171485.
5
Perspectives in multiple sclerosis health care: special focus on the costs of multiple sclerosis.多发性硬化症医疗保健的视角:特别关注多发性硬化症的成本
Autoimmun Rev. 2006 Oct;5(8):511-6. doi: 10.1016/j.autrev.2006.02.001. Epub 2006 Mar 10.
6
A cost evaluation of multiple sclerosis.多发性硬化症的成本评估。
J Neurovirol. 2000 May;6 Suppl 2:S191-3.
7
Estimate of the cost of multiple sclerosis in Spain by literature review.通过文献综述对西班牙多发性硬化症的成本估算。
Expert Rev Pharmacoecon Outcomes Res. 2017 Aug;17(4):321-333. doi: 10.1080/14737167.2017.1358617. Epub 2017 Jul 28.
8
Costs and quality of life of multiple sclerosis in Austria.奥地利多发性硬化症的成本与生活质量
Eur J Health Econ. 2006 Sep;7 Suppl 2:S14-23. doi: 10.1007/s10198-006-0382-x.
9
The economic impact of multiple sclerosis in Australia in 2010.2010 年澳大利亚多发性硬化症的经济影响。
Mult Scler. 2013 Oct;19(12):1640-6. doi: 10.1177/1352458513488230. Epub 2013 May 7.
10
Estimation of the cost of MS in Europe: extrapolations from a multinational cost study.欧洲多发性硬化症成本估算:基于一项跨国成本研究的推断
Mult Scler. 2007 Sep;13(8):1054-64. doi: 10.1177/1352458507077941. Epub 2007 Jul 10.

引用本文的文献

1
Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab.使用奥瑞珠单抗进行一线治疗与二线或后续治疗的多发性硬化症患者的真实世界临床和经济结果
Neurol Ther. 2023 Oct;12(5):1709-1728. doi: 10.1007/s40120-023-00523-3. Epub 2023 Jul 17.
2
Socioeconomic status of the elderly MS population compared to the general population: a nationwide Danish matched cross-sectional study.老年多发性硬化症患者群体与普通人群的社会经济状况比较:一项丹麦全国性匹配横断面研究。
Front Neurol. 2023 Jun 13;14:1214897. doi: 10.3389/fneur.2023.1214897. eCollection 2023.
3
The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
美国多发性硬化症的经济负担:直接和间接成本的估计。
Neurology. 2022 May 3;98(18):e1810-e1817. doi: 10.1212/WNL.0000000000200150. Epub 2022 Apr 13.
4
Economics of Multiple Sclerosis Disease-Modifying Therapies in the USA.美国多发性硬化症疾病修正治疗的经济学
Curr Neurol Neurosci Rep. 2021 May 5;21(7):28. doi: 10.1007/s11910-021-01118-x.
5
The catastrophic out-of-pocket health expenditure of multiple sclerosis patients in Iran.伊朗多发性硬化症患者灾难性的自付医疗费用。
BMC Health Serv Res. 2021 Mar 20;21(1):257. doi: 10.1186/s12913-021-06251-4.
6
Health economics of disease-modifying therapy for multiple sclerosis in the United States.美国多发性硬化症疾病修正疗法的卫生经济学
Ther Adv Neurol Disord. 2021 Feb 17;14:1756286420987031. doi: 10.1177/1756286420987031. eCollection 2021.
7
Walking impairment in patients with multiple sclerosis - a new therapeutic approach and clinical potential of dalfampridine extended release tablets.多发性硬化症患者的行走障碍——达氟吡啶缓释片的一种新治疗方法及临床潜力
Degener Neurol Neuromuscul Dis. 2012 Jun 22;2:53-64. doi: 10.2147/DNND.S19839. eCollection 2012.
8
The economic impact of multiple sclerosis to the patients and their families in Norway.挪威多发性硬化症患者及其家庭的经济负担。
Eur J Health Econ. 2018 Dec;19(9):1243-1257. doi: 10.1007/s10198-018-0971-5. Epub 2018 Apr 21.
9
Triaging Patients with Multiple Sclerosis in the Emergency Department: Room for Improvement.急诊科对多发性硬化症患者的分诊:仍有改进空间。
Int J MS Care. 2017 Nov-Dec;19(6):290-296. doi: 10.7224/1537-2073.2016-069.
10
Comprehensive population-based determination of pediatric multiple sclerosis health care costs.基于人群的小儿多发性硬化症医疗保健费用综合测定。
Neurol Neuroimmunol Neuroinflamm. 2016 Dec 19;4(1):e314. doi: 10.1212/NXI.0000000000000314. eCollection 2017 Jan.